This article first appeared on GuruFocus .
iShares Biotechnology ETF ( IBB ) extended its run of one-sided ETF activity on Monday, Oct. 26, adding $104.2 million in net new positions against $104.2 million in gross trades. The fund increased 232 positions and decreased none, a day of broad accumulation across its portfolio. The buying came as the fund carried $11.03 billion in assets under management.
What did IBB buy on Monday?
Its largest buys by dollar value were GILD ($9.1 million), AMGN ($8.6 million) and VRTX ($7.9 million).
| Stock |
Shares changed |
Value |
Position |
|---|---|---|---|
| GILEAD SCIENCES ( GILD ) |
+57,070 |
$9.1M |
8.69% of fund |
| AMGEN INC ( AMGN ) |
+19,420 |
$8.6M |
8.28% of fund |
| VERTEX PHARMACEUTICALS ( VRTX ) |
+15,330 |
$7.9M |
7.61% of fund |
| REGENERON PHARMACEUTICALS ( REGN ) |
+7,320 |
$5.9M |
5.67% of fund |
| MODERNA ( MRNA ) |
+26,990 |
$5.4M |
5.15% of fund |
Gilead Sciences led the largest buys with 57,070 shares added, worth $9.1 million and representing 8.69% of assets. Amgen followed with 19,420 shares purchased for $8.6 million at an 8.28% weight, while Vertex Pharmaceuticals added 15,330 shares valued at $7.9 million and 7.61% of assets. Regeneron Pharmaceuticals drew 7,320 shares for $5.9 million at 5.67%, and Moderna added 26,990 shares worth $5.4 million at 5.15%. All five were existing positions, with no new positions opened and no holdings fully exited on the day.
How does IBB invest?
iShares Biotechnology ETF ( IBB ) is an equity sector healthcare fund holding 225 stocks, with 50.7% of assets in its 10 largest holdings. Healthcare accounts for 100.0% of the stocks that could be classified. By market cap, 75.7% is large-cap, 19.2% mid-cap and 5.1% small-cap. The fund charges an expense ratio of 0.44%. Its top holdings are Gilead Sciences at 8.69%, Amgen at 8.28%, Vertex Pharmaceuticals at 7.61%, Regeneron Pharmaceuticals at 5.67% and Moderna at 5.15%. It has a GF Score of 65, a P/E of 24.52, a P/B of 5.26, a dividend yield of 0.02% and a year-to-date return of 25.85%.
iShares Biotechnology ETF ( NASDAQ:IBB ) at a glance
| Measure |
Value |
|---|---|
| Category |
Equity Sector Healthcare |
| Asset class |
Equity |
| Holdings |
225 |
| Top 10 holdings |
50.7% of assets |
| Largest sectors |
Healthcare 100.0% |
| Expense ratio |
0.44% |
| Market-cap mix |
Large 75.7%, mid 19.2%, small 5.1% |
| 65/100 |
|
| P/E |
24.52 |
| P/B |
5.26 |
| Dividend yield |
0.02% |
| Year-to-date return |
+25.85% |
| Top holdings |
GILD (8.69%), AMGN (8.28%), VRTX (7.61%), REGN (5.67%), MRNA (5.15%) |
See the full iShares Biotechnology ETF profile , or compare it with similar funds in the ETF Screener . For the stock behind its biggest buy, see GILD's GF Value page and guru trades .
Track the latest ETF buying and selling trends and search funds in the GuruFocus ETF Screener .
What should investors watch next for IBB?
Watch whether the fund's next holdings update shows continued one-way accumulation or a shift toward trimming, and whether the weight of its 10 largest holdings keeps climbing as the biggest positions absorb new capital.
Based on holdings changes reported by iShares Biotechnology ETF ( IBB ) for Oct. 26, 2026, US-listed stocks only.
